What Is Transdermal Verapamil 15% Gel?
Transdermal Verapamil 15% Gel is a painless, non-invasive, treatment for fibrotic tissue disorders such as Peyronie's disease that was developed and patented by PDLabs. Since 1998 PDLabs Transdermal Verapamil 15% Gel has been prescribed for over 13,000 patients. It is a prescription compounded medication that is applied directly to the skin twice a day. Verapamil belongs to the class of medications known as calcium channel blockers. The gel has been designed to carry the verapamil through the skin and deliver it to the Peyronie's plaque. The proprietary formula allows for minimal absorption into the blood, while maximizing the concentration of verapamil in the plaque and surrounding tissue.
How Does It Work For Peyronie's Disease?
As with many medications, the exact way Transdermal Verapamil 15% Gel helps Peyronie's disease is not entirely understood. It is proposed that two different processes are taking place. The first allows for the progression of Peyronie's disease to be slowed or stopped and second for the Peyronie's plaque to actually be reduced, which allows for the symptoms of the condition to be reduced or eliminated. Both of these processes are effected by verapamil's ability as a calcium channel blocker to block calcium.
Cells known as fibroblasts are responsible for the production of the primary components of the Peyronie's plaque such as collagen, fibronectin and glycosaminoglycans. Research has shown that the process by which these components are released out of the fibroblast requires calcium.  It has been found that calcium channel blockers have the ability to decrease the production of collagen and fibronectin and their release from the fibroblast.  A study has also shown that the large increase of Peyronie's fibroblasts is markedly impaired by verapamil, even at low doses.  This research is the basis of why it is thought that using Transdermal Verapamil 15% Gel in the inflammatory or early stages of Peyronie's disease, may prevent the condition from being as severe as it might have been without any treatment.
Fibroblasts are also responsible for the production of an enzyme called collagenase. This enzyme is responsible for breaking down or remodeling the excess collagen that makes up Peyronie's plaque. Research has demonstrated that calcium channel blockers such as verapamil have the ability to increase the activity of collagenase, which enhances the remodeling of scars in burn victims.  It was also found in experiments with bovine fibroblasts that exposure to verapamil increased collagenase activity.  Peyronie's disease is thought to be similar to other wound disorders such as keloids and hypertrophic scars. Research on the use of verapamil in keloids has suggested that it may increase procollagenase production, meaning that verapamil may be capable of increasing collagen breakdown.  Although this research was not done on fibroblasts from Peyronie's plaque, it is theorized that fibroblasts from Peyronie's plaque will respond in a similar way. This theory is supported by improvements seen in plaque size when verapamil has been introduced into the Peyronie's plaque. The increase in collagenase activity after exposing the fibroblasts to verapamil helps to explain how Transdermal Verapamil 15% Gel can remodel an already formed and stable Peyronie's plaque into more healthy and elastic tissue. The remodeling of the tissue and return of the elasticity allows for the symptoms of Peyronie's disease to be reduced or eliminated.
The illustration below shows the two proposed mechanisms of action, magnified to the level of the fibroblast.
 Aggeler J, Frish SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts.. J. Cell Biol. 1984;98:1662. MEDLINE
 Anderson MS, Shankey TV, Lubrano T, Mulhall JP. Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res. 2000;12:S25.
 Lee RC, Doong H, Jellema AF. The response of burn scars to intralesional verapamil. Arch Surg. 1994;129:107. MEDLINE
 Lee RC, Ping JA. Calcium antagonist retard extracellular matrix production in connective tissue equivalent. J Surg Res. 1990;49:463. MEDLINE
 Doong H, Dissanayake S, Gowrishankar TR, LaBarbera MC, Lee RC. The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. J Burn Care Rehabil. 1996;17:497. MEDLINE